Thank u @Heart_SCCT @jolson106
Was an honor serving on #ASM committee #SCCT2022 & congrats @ghoshhajra for leading this team
My takeaways:
1) #ISCHEMIA captured current landscape of functional testing & put anatomy vs ischemia discussions in the center
ahajournals.org/doi/10.1161/CI…
2) We learned from those excluded from the trial as much as we did from those included #CIAO-ISCHEMIA
#SCCT2022
ahajournals.org/doi/10.1161/CI…
3) #DISCHARGE trial will make way for cathlabs to focus on complex procedures as #YesCCT assumes most diagnostic evaluations
nejm.org/doi/full/10.10…
#SCCT2022 @NEJM
4.#FFRCT pro & cons: provides spectrum of ischemia rather than a binary yes/no & it is a work in progress
#PACIFICTrial long term results anticipated
sciencedirect.com/science/articl…
#SCCT2022
5.Plaque characterization provides more than % stenosis & a step in the direction of vulnerable plaque/patient. Work in progress. #SCCT2022
6.#CACS how it compares to current functional testing & it’s NPV.. CON-beyond calcium: % stenosis, consistency & early detection/prevention
#SCOTHEART nejm.org/doi/full/10.10… @NEJM
#SCCT2022
7. #PROMISE #SCCT2022 How age is factored into the decision making
@JAMANetwork
jamanetwork.com/journals/jamac…
Finally: #Advocacy #SCCT2022 @Heart_SCCT @EricWillMD
-Aligned w @ACCinTouch @ditchhaporia
-Create educational dossier to speak same language
-Advocate reimbursement
Slide courtesy @Ahmad_M_Slim
@bjcohenmd @HeartOTXHeartMD
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.